Abstract
Purpose :
Intravitreal Injection of anti vascular endothelial growth factor (anti-VEGF) is increasingly used to treat retinopathy of prematurity (ROP). The purpose of this study is to describe the 8 year real word expirece of CT Unit of Policlinico Gemelli of Rome
Methods :
This retrospective study reviewed ROP infants treated with intravitreal injection of Ranibizumab as the first treatment from January 2016 and November 2023. Infants treated with ranibizumab were identified for review of their clinica outcomes. We analysed the data of infants wit reactivation.
Results :
A total of 1045 infants were screene d for ROP. Forty-one infants with a mean gestational age of 30±2.2 weeks weeks and a mean birth weight of 1230 ± 234.2 g. receaived IVR at mean postmenstrual age (PMA) of 38± 2.5 weeks. All treated eyes demonstrated initial regression of ROP. However, ROP reactivation occurred in 3 eyes of 2 patients, at an average of 10.6 ± 2.9 weeks after treatment. None of these eyes had retinal detachment. A second dose IVR was administered and all 3 eyes showed regression with complete retinal vascularisation, at a mean PMA of 58 ± 4.2 weeks.
Conclusions :
IVR is beneficial as an initial and subsequent treatment for type 1 ROP or APROP. GA are potential predictor of complete retinal vascularization in ROP infants tretated with IVR . A long-term follow-up until complete retinal vascularisation is recommended to avoid disease reactivation.
This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.